NCT01486966 - Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

insulin detemir

Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4

DRUG

insulin aspart

Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4

DRUG

insulin NPH

Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4

DRUG

human soluble insulin

Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4

DRUG

metformin

For subjects previously treated with metformin, the dosage and frequency will be kept unchanged

Trial Locations (6)

Novo Nordisk Investigational Site, Beijing

Novo Nordisk Investigational Site, Shanghai

Novo Nordisk Investigational Site, Shanghai

Novo Nordisk Investigational Site, Wuxi

Novo Nordisk Investigational Site, Nanchang

Novo Nordisk Investigational Site, Chongqing